P

Porton Pharma Solutions Ltd
SZSE:300363

Watchlist Manager
Porton Pharma Solutions Ltd
SZSE:300363
Watchlist
Price: 16.65 CNY 1.46% Market Closed
Market Cap: 9.1B CNY
Have any thoughts about
Porton Pharma Solutions Ltd?
Write Note
Porton Pharma Solutions Ltd
/
Cash Flow Statement
/
Cash from Investing Activities

Porton Pharma Solutions Ltd
Cash from Investing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Porton Pharma Solutions Ltd
Cash from Investing Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Investing Activities CAGR 3Y CAGR 5Y CAGR 10Y
P
Porton Pharma Solutions Ltd
SZSE:300363
Cash from Investing Activities
-¥654m
CAGR 3-Years
1%
CAGR 5-Years
-41%
CAGR 10-Years
-16%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Cash from Investing Activities
¥1.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Cash from Investing Activities
¥7B
CAGR 3-Years
N/A
CAGR 5-Years
61%
CAGR 10-Years
N/A
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Cash from Investing Activities
-¥1.9B
CAGR 3-Years
N/A
CAGR 5-Years
9%
CAGR 10-Years
-25%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Cash from Investing Activities
-¥1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
3%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Cash from Investing Activities
-¥81.9m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Porton Pharma Solutions Ltd
Glance View

Market Cap
9.1B CNY
Industry
Pharmaceuticals

Porton Pharma Solutions Ltd., rooted in the vibrant landscape of China's pharmaceutical sector, has strategically navigated its way to becoming a pivotal player in the global Contract Development and Manufacturing Organization (CDMO) industry. Founded in 2005, the company harnesses the intricate synergy between chemistry and biology to drive its core operations. Porton specializes in providing a comprehensive suite of services ranging from early drug development to commercial-scale manufacturing. The company's business model thrives on forming collaborative partnerships with global pharmaceutical and biotechnology firms, offering customized solutions tailored to specific drug production needs. By acting as an extension of its clients' research and development teams, Porton effectively reduces the time and investment required for its clients to bring new drugs to market, catalyzing its own revenue through long-standing service agreements. The essence of Porton’s value proposition lies in its robust technological capabilities and commitment to compliance with international quality standards, which ensures client trust and repeat business. Porton's facilities are outfitted with cutting-edge technologies that support complex chemical synthesis and advanced bioprocessing, allowing them to expertly handle high-potency and complex molecules. Additionally, the company leverages its strategic geographic advantage in China to offer competitive pricing while maintaining quality excellence, a crucial factor in contracting agreements. Through continuous investments in research and development, and a commitment to operational efficiency, Porton Pharma Solutions Ltd. not only accelerates its clients' drug development timelines but also enhances its own profitability, positioning itself as a leader in the evolving CDMO landscape.

Intrinsic Value
20.76 CNY
Undervaluation 20%
Intrinsic Value
Price
P
What is Intrinsic Value?

See Also

What is Porton Pharma Solutions Ltd's Cash from Investing Activities?
Cash from Investing Activities
-654m CNY

Based on the financial report for Sep 30, 2024, Porton Pharma Solutions Ltd's Cash from Investing Activities amounts to -654m CNY.

What is Porton Pharma Solutions Ltd's Cash from Investing Activities growth rate?
Cash from Investing Activities CAGR 10Y
-16%

Over the last year, the Cash from Investing Activities growth was 52%. The average annual Cash from Investing Activities growth rates for Porton Pharma Solutions Ltd have been 1% over the past three years , -41% over the past five years , and -16% over the past ten years .

Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.